Introduction
============

According to the latest definition, formulated in 2010, adverse effect is a harmful and unintentionally caused reaction to a medicine.[@b1-ppa-10-1461] Adverse drug reactions (ADRs) are a common cause of morbidity and mortality, with contribution of numerous risks factors. It is estimated that ADRs could be prevented iñ50% of cases.[@b2-ppa-10-1461]--[@b5-ppa-10-1461]

Of all cardiovascular drugs, most adverse effects are caused by β-blockers, angiotensin converting enzyme inhibitors, and calcium channel blockers.[@b6-ppa-10-1461],[@b7-ppa-10-1461]

β-Blockers are recommended as a first-line agent for various diseases, including heart failure, hypertension, and angina, as well as after myocardial infarction.[@b8-ppa-10-1461],[@b9-ppa-10-1461] However, β-blocker therapy often produces variable responses among patients.[@b10-ppa-10-1461],[@b11-ppa-10-1461] Individual response to β-blockers in other clinical settings is substantially influenced by genetic variation in adrenergic signaling[@b12-ppa-10-1461] and drug metabolism pathways, most notably in the cytochrome P450 2D6 (CYP2D6) enzyme.[@b13-ppa-10-1461]--[@b15-ppa-10-1461]

CYP2D6 is one of the most important metabolic enzymes, responsible for the biotransformation of 25% of all drugs, including most β-blockers.[@b16-ppa-10-1461],[@b17-ppa-10-1461] The observed interindividual variation in CYP2D6 enzyme activity is mainly due to its genetic polymorphism, which significantly affects the metabolism of \~50% of its substrate drugs.[@b18-ppa-10-1461] More than 150 alleles lead to four distinct phenotypes of drug metabolism,[@b19-ppa-10-1461] described as ultrarapid metabolizer, extensive metabolizer (EM), intermediate metabolizer, and poor metabolizer (PM). However, \~98% of the PM phenotype can be explained by three single-nucleotide polymorphisms (SNPs), ie, rs35742686 (2549delA), rs3892097 (1846G\>A), and rs5030655 (1707delT) corresponding to alleles \**3*, \**4*, and \**6*, respectively, or a complete deletion of *CYP2D6* (\**5*).[@b20-ppa-10-1461]--[@b22-ppa-10-1461] In addition to the loss of function, CYP2D6 enzyme activity could be significantly decreased due to gene polymorphism, and the SNPs leading to this effect include rs1065852 (100C\>T, *CYP2D6*\**10*)[@b23-ppa-10-1461] present in 20% of the European population.[@b24-ppa-10-1461]

The aim of the present study was to examine the frequency of *CYP2D6* PM alleles (\**3*, \**4*, \**5*, \**6*, and \**10*) in a Montenegrin population, and to determine its impact on developing ADRs of β-blockers in a hospitalized cardiac patient population.

Methods
=======

A prospective study was conducted in the Cardiology Center of the Clinical Center of Montenegro and included 138 patients who had received any β-blocker in their therapy.

Before enlisting in the study, patients were given all necessary information about the study design, after which they signed an informed consent. The ethics committee of the Clinical Center of Montenegro approved the implementation of the research, which was conducted in accordance with the Declaration of Helsinki.

The exclusion criteria were as follows: age younger than 18 years and older than 80 years, dementia or other causes of disorientation, severe illness (eg, cardiogenic shock, pulmonary edema, etc), hematological disorders, significant renal and liver failure, short period of hospitalization (\<3 days), and patient's refusal to participate in the trial. In addition, coadministration with major CYP2D6 inhibitors was contraindicated (ie, fluoxetin, levomepromazine, lobelin, methadone, paroxetine, quinidine, and trifluperidol).[@b18-ppa-10-1461]

We defined ADRs according to the definition of the World Health Organization (WHO),[@b1-ppa-10-1461] and for each adverse reaction determined the causal relationship with the drug according to the Naranjo algorithm.[@b25-ppa-10-1461] Also, we determined the severity of the ADRs according to the criteria of the WHO, as well as the type (A: based on the drug's pharmacologic properties; B: idiosyncratic, unexpected; C: chronic effects related to long-term drug use), according to the classification proposed by Edwards and Aronson.[@b26-ppa-10-1461]

For the study, a special questionnaire was designed ([Figure S1](#SD1-ppa-10-1461){ref-type="supplementary-material"}). It consisted of questions about the medication that the patient received during hospitalization in the Center of Cardiology.

The interview was conducted in three steps. First, the patients were asked the standard open question: "Have you noticed or felt any adverse reaction of the drug?" If the answer was yes, the ADRs were recorded. Then the patients were asked about complaints to the various organ systems: these questions helped the patients to "remember" the ADRs. Finally, the patients were asked for adverse reactions mentioned in the "Summary of Product Characteristics", in relation to drugs administered during hospitalization. Data from the patients' medical charts, laboratory tests, and other available parameters were observed and combined with the data from the questionnaire.

All patients who received β-blockers were *CYP2D6* genotyped. On the basis of available literature[@b27-ppa-10-1461],[@b28-ppa-10-1461] and *CYP2D6* allele nomenclature,[@b29-ppa-10-1461] for the purpose of the study, five variants were identified and included in the analysis. These variants are considered to be the most common genetic determinants of CYP3D6 PM phenotypes: *CYP2D6*\**3* (2549delA, rs35742686), *CYP2D6*\**4* (1846G\>A, rs3892097), *CYP2D6*\**5* (gene deletion), *CYP2D6*\**6* (1707delT, rs5030655), and *CYP2D6*\**10* (100C\>T, rs1065852).

DNA was extracted from whole-blood samples using the PureLink^®^ genomic DNA kit (Thermo Fisher Scientific, Waltham, MA, USA). Genotyping for *CYP2D6*\**3*, \**4*, and \**6* was carried out using the real-time PCR method on a Mastercycler^®^ ep realplex[@b2-ppa-10-1461] (Eppendorf AG, Hamburg, Germany), with the use of TaqMan Genotyping Master Mix 2X (Thermo Fisher Scientific) and the corresponding TaqMan DME genotyping Assays (Thermo Fisher Scientific). Genotyping for *CYP2D6*\**5* and \**10* was conducted according to the previously described long-PCR tetra-primer[@b30-ppa-10-1461],[@b31-ppa-10-1461] and allele-specific PCR[@b32-ppa-10-1461] methods, with minor modifications. Analyses were performed at the Faculty of Medical Sciences, University of Kragujevac.

Statistical data analysis was performed using IBM SPSS Statistics 22 (IBM Corporation, Armonk, NY, USA). Results are presented as frequency, percent, and mean ± standard deviation. For parametric data, independent sample *t*-test was used to test differences between groups. The Mann--Whitney *U*-test was used for obtaining the significance between ordinal data. The chi-squared test or Fisher's exact test was used to test the differences between nominal data (frequencies), including Hardy--Weinberg equilibrium. The association between potential risk factors and ADRs was evaluated using binary logistic regression, expressing the strength of association by crude and adjusted odds ratio with 95% confidence intervals. A *P*-value of \<0.05 was considered significant.

Results
=======

One hundred and thirty-eight patients on β-blocker therapy were included in the study. Of those, 66 (47.8%) patients were treated with metoprolol (dose 25--100 mg), 36 (26.1%) with carvedilol (dose 6.25--50 mg), 33 (23.9%) with bisoprolol (dose 2.5--10 mg), and three (2.2%) with nebivolol (dose 5 mg). The basic characteristics of the patients and the frequencies of *CYP2D6* variants, alleles, and genotypes are given in [Tables 1](#t1-ppa-10-1461){ref-type="table"} and [2](#t2-ppa-10-1461){ref-type="table"}, respectively.

ADRs to β-blockers were observed in 15 (10.9%) patients. Most ADRs were related to the use of carvedilol and metoprolol (six patients, ie, 8.0% each), followed by bisoprolol (three patients, ie, 4.0%). The most common ADRs were bradycardia (44.4%), dizziness (22.2%), headache (11.1%), hypotension (5.5%), cold lower extremities (5.5%), pain in the extremities (5.5%), and nightmares (5.5%). The characteristics of ADRs to β-blockers and the levels of intervention are given in [Table 3](#t3-ppa-10-1461){ref-type="table"}.

Genotyping of patients receiving β-blockers showed that more than half belonged to the group of EMs (54.3%). The frequency of PMs was 37.6%, 5.1% of respondents had no enzymatic activity, while 1.4% of patients had intermediate and very PM phenotypes. There was a statistically significant difference in the frequency of ADRs in relation to genetically determined enzymatic activity (*P*\<0.001), with the occurrence of ADRs significantly correlating with slower CYP2D6 metabolism ([Figure 1](#f1-ppa-10-1461){ref-type="fig"}).

The influence of different predictors on the outcome of interest (ie, ADRs to β-blockers) was analyzed in two steps. First, a univariate logistic regression model was used to assess the influence of single predictors, and a subsequent multivariate model analyzed the simultaneous influence of all predictors confirmed as significant in the single predictor analysis.

In the univariate logistic regression model, statistically significant predictors of ADRs to β-blockers were the number of days of hospitalization (*P*=0.019), enzyme activity (PMs \[*P*=0.016\], and very PM and metabolizer without enzyme activity \[*P*\<0.001\] compared to EM and intermediate metabolizer as the reference category) and the concomitant use of other drugs that are metabolized by the same CYP enzyme system (*P*=0.001).

The multivariate logistic regression model included a statistically significant predictor from the univariate logistic regression model. As regards the CYP2D6 enzyme activity in the sample analyzed, it was necessary to compress a small number of variables into fewer categories: 1) EM and intermediate metabolizer and 2) PMs, very PMs, and metabolizers without enzyme activity. The multivariate logistic regression model was statistically significant (*P*\<0.001), without significant multicollinearity between predictors. The interaction of predictors in the model was not statistically significant. In other words, the predictors were orthogonal (ie, they were not collinear), and the statistical interference on the model was reliable.

In the multivariate logistic regression model, statistically significant predictors of ADRs to β-blockers were longer hospitalization (*P*=0.008), slower enzymatic activity (*P*\<0.001), and concomitant use of other drugs that are metabolized by CYP2D6 (*P*\<0.001) ([Table 4](#t4-ppa-10-1461){ref-type="table"}).

Discussion
==========

β-Blockers are an important class of cardiovascular drugs used in hypertension, heart failure, and acute myocardial infarction, which represent one of four leading agents that reduce cardiovascular mortality and morbidity. Although \>100 β-blockers have been developed, only \~30 are in clinical use.[@b33-ppa-10-1461]

Polypharmacy, a common practice in cardiovascular pharmacotherapy, may give rise to ADRs. The prevalence of cardiovascular drug-induced adverse reactions is 2.4 times higher compared to other drugs.[@b34-ppa-10-1461] Numerous studies have shown that the administration of β-blockers is associated with higher incidences of ADRs compared to other cardiovascular drugs.[@b35-ppa-10-1461],[@b36-ppa-10-1461] The present study was conducted in order to analyze ADRs in patients with cardiovascular diseases treated with β-blockers, and to assess the modulating role of *CYP2D6* SNPs.

The results of our study showed that ADRs to β-blockers appear in every ninth patient, which is twice compared to the data in the literature.[@b6-ppa-10-1461] This may be partly due to the use of different drugs from this class studied or a different study design. The most common ADRs observed in our study population were bradycardia and dizziness, while other adverse effects, such as fatigue, cold hands, headache, stomach upset, constipation, and diarrhea, were rare. These results are in accordance with the data from the literature.[@b33-ppa-10-1461]--[@b35-ppa-10-1461] As expected, the ADRs observed were mainly type A reactions (based on the drug's pharmacologic properties), which could be explained by the study design, target population, and the well-known β-blocker safety pattern. In particular, the type A reactions are dose-related and more likely to occur in PMs.

It is well known that polymorphism of the *CYP2D6* gene plays an important role in the biotransformation of β-blockers.[@b22-ppa-10-1461],[@b37-ppa-10-1461] Numerous studies have found the *CYP2D6* genotype to be a major determinant of plasma concentration of metoprolol,[@b13-ppa-10-1461],[@b38-ppa-10-1461]--[@b41-ppa-10-1461] the most frequently prescribed β-blocker.[@b13-ppa-10-1461] However, reports on the adverse effects of β-blockers in relation to *CYP2D6* polymorphism are conflicting, as some authors observed that the PM genotype conveys significantly higher risk for the development of ADRs[@b12-ppa-10-1461],[@b13-ppa-10-1461],[@b42-ppa-10-1461]--[@b44-ppa-10-1461] while others did not detect any significant difference in drug response among the *CYP2D6* genotype groups.[@b39-ppa-10-1461],[@b40-ppa-10-1461],[@b45-ppa-10-1461]--[@b47-ppa-10-1461] In a retrospective study, Wuttke et al[@b12-ppa-10-1461] identified 24 patients treated with metoprolol who had experienced pronounced adverse effects. Genotyping revealed a fivefold higher frequency of PM in this group compared to the control population, with the CYP2D6 PM phenotype exhibiting up to tenfold higher plasma concentrations of metoprolol compared to EMs. Goryachkina et al,[@b13-ppa-10-1461] investigating the effect of *CYP2D6* polymorphism in 187 acute myocardial infarction patients on metoprolol treatment, observed the most pronounced bradycardia in genotypically PMs. A similar association was observed in several larger trials, including the MERIT-HF[@b44-ppa-10-1461] and the Rotterdam Study,[@b42-ppa-10-1461] reporting significantly lower heart rates and blood pressure in carriers of a *CYP2D6*\**4* defective allele. On the other hand, there have been a number of reports showing no relationship between metoprolol response and the *CYP2D6* genotype,[@b39-ppa-10-1461],[@b40-ppa-10-1461],[@b45-ppa-10-1461],[@b47-ppa-10-1461] but the lack of significance was usually due to the small sample size,[@b39-ppa-10-1461],[@b40-ppa-10-1461],[@b45-ppa-10-1461],[@b47-ppa-10-1461] lack of genotyping data on all important PM *CYP2D6* SNPs,[@b45-ppa-10-1461],[@b47-ppa-10-1461] or the presence of confounding variables that are likely to obscure differences in clinical effects.[@b45-ppa-10-1461]

In the present study, we examined the frequency and effect of the most important *CYP2D6* PM SNPs in patients treated with β-blockers. The results showed that most of our patients were EMs, while the least frequent were intermediate and very PMs. These data are consistent with those obtained in other white populations.[@b48-ppa-10-1461]--[@b52-ppa-10-1461] As for the ADRs to β-blockers, they were significantly more common in carriers of the *CYP2D6* genotype, which predicts poor metabolism. This corresponds well with the reports of higher incidence of ADRs in CYP2D6 PMs,[@b10-ppa-10-1461],[@b18-ppa-10-1461],[@b53-ppa-10-1461]--[@b55-ppa-10-1461] indicating the importance of *CYP2D6* genotyping in Montenegrin patients on β-blockers. Further studies, including genotyping for duplication of the functional *CYP2D6* gene, might further reveal the possible effect of the ultrarapid metabolizer phenotype on the resistance to β-blockers therapy. In addition to the CYP2D6 activity, our study showed that ADRs to β-blockers are more likely to occur in patients with comedications and longer hospitalization, which fits into the well-known pattern. Significance in the multivariate regression model used without collinearity between predictors implies that the risk factors for the ADRs to β-blockers could be reliably identified.

As regards the possible limitations, β-blocker plasma monitoring could significantly improve the reliability of our study, although these drugs do not fulfill the criteria for routine therapeutic drug monitoring.[@b56-ppa-10-1461]

Conclusion
==========

Our study showed that the adverse reactions to β-blockers could be predicted by the length of hospitalization, genotype-inferred CYP2D6 PM phenotype, and the concomitant use of other CYP2D6-metabolized drugs. Therefore, in hospitalized patients with polypharmacy that includes β-blockers, *CYP2D6* genotyping might be useful in detecting those at risk of ADRs.

Supplementary material
======================

###### 

Questionnaire regarding adverse drug reaction.

**Abbreviation:** BMI, body mass index.
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###### 

Baseline data of the patients

  Characteristic                         Patients on β-blocker therapy (n=138)
  -------------------------------------- ---------------------------------------
  Age (years), mean ± SD                 59.5±9.8
  Males, n (%)                           98 (71)
  Body mass index (kg/m^2^), mean ± SD   28.2±3.8
  Active smokers, n (%)                  55 (39.9)
  Arterial hypertension, n (%)           106 (76.8)
  Diabetes mellitus, n (%)               32 (23.2)
  Hypercholesterolemia, n (%)            63 (45.7)
  Family history of CAD, n (%)           49 (35.5)
  Obesity, n (%)                         34 (24.6)
  Number of drugs, median (range)        8 (2--16)
  Duration of hospitalization            6 (1--29)
  (days), median (range)                 
  ADRs, n (%)                            15 (10.9)

**Abbreviations:** SD, standard deviation; CAD, coronary artery disease; ADR, adverse drug reaction.

###### 

Frequencies of *CYP2D6* gene variations, alleles, and genotypes in Montenegrin patients on β-blocker therapy

  Population genetics parameters   Observed frequency   95% confidence interval
  -------------------------------- -------------------- -------------------------
  Gene variation                                        
   2549delA                        0.033 (9/276)        0.017--0.062
   1846G\>A                        0.181 (50/276)       0.140--0.231
   Gene deletion                   0.014 (4/276)        0.004--0.038
   1707delT                        0.025 (7/276)        0.011--0.053
   100C\>T                         0.130 (36/276)       0.096--0.176
  Allele                                                
   *CYP2D6*\**1*                   0.739 (204/276)      0.684--0.787
   *CYP2D6*\**3*                   0.029 (8/276)        0.014--0.057
   *CYP2D6*\**4*                   0.178 (49/276)       0.137--0.227
   *CYP2D6*\**5*                   0.014 (4/276)        0.004--0.038
   *CYP2D6*\**6*                   0.025 (7/276)        0.011--0.053
   *CYP2D6*\**10*                  0.014 (4/276)        0.004--0.038
  **Genotype**                                          
  Extensive metabolizer                                 
   *CYP2D6*\**1/*\**1*             0.543 (10/138)       0.460--0.624
  Intermediate metabolizer                              
   *CYP2D6*\**1/*\**10*            0.014 (2/138)        0.001--0.055
  Poor metabolizer                                      
   *CYP2D6*\**1/*\**3*             0.051 (7/138)        0.023--0.103
   *CYP2D6*\**1/*\**4*             0.275 (38/138)       0.208--0.355
   *CYP2D6*\**1/*\**5*             0.014 (2/138)        0.001--0.055
   *CYP2D6*\**1/*\**6*             0.036 (5/138)        0.014--0.085
  Very poor metabolizer                                 
   *CYP2D6*\**4/*\**10*            0.014 (2/138)        0.001--0.055
  No enzyme activity                                    
   *CYP2D6*\**3/*\**5*             0.007 (1/138)        0.000--0.045
   *CYP2D6*\**4/*\**4*             0.022 (3/138)        0.005--0.065
   *CYP2D6*\**4/*\**5*             0.007 (1/138)        0.000--0.045
   *CYP2D6*\**4/*\**6*             0.014 (2/138)        0.001--0.055

###### 

Characteristics of detected ADRs

  Characteristic                                 ADRs in patients on β-blocker therapy (n=15) (%)
  ---------------------------------------------- --------------------------------------------------
  Type                                           
   Type A                                        15 (100)
   Type B                                        0 (0)
   Type C                                        0 (0)
  Causality                                      
   Certain                                       0 (0)
   Probable                                      3 (20)
   Possible                                      12 (80)
  Level of intervention                          
   Level 1 (no change in dose)                   3 (20)
   Level 2 (dose changed or drug stopped)        10 (66.66)
   Level 3 (drug stopped + additional therapy)   2 (13.33)
   Level 4 (transfer to intensive care unit)     0 (0)
  Severity                                       
   Serious ADRs                                  4 (26.66)
   Nonserious ADRs                               11 (73.33)
  Outcome                                        
   Recovery without consequences                 15 (100)
   Recovery with consequences                    0 (0)

**Abbreviation:** ADR, adverse drug reaction.

###### 

Multivariate logistic regression with ADRs on β-blockers as the dependent variable

  Independent variable                                                                Multivariate logistic regression   
  ----------------------------------------------------------------------------------- ---------------------------------- ---------
  Number of days of hospitalization                                                   1.13 (1.03--1.24)                  0.008
  Enzyme activity (two categories)                                                    34.60 (4.80--49.31)                \<0.001
  Concomitant use of other drugs that are metabolized by the same CYP enzyme system   25.44 (5.01--29.29)                \<0.001

**Abbreviations:** ADR, adverse drug reaction; OR, odds ratio; CI, confidence interval; CYP, cytochrome P450.
